Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (DE:LLY)
XETRA:LLY
LLY Stock Chart & Stats
€863.60
€1.80(0.24%)
At close: 4:00 PM EST
€863.60
€1.80(0.24%)
Day’s Range― - ―
52-Week Range€535.80 - €971.10
Previous CloseN/A
Volume143.00
Average Volume (3M)2.15K
Market Cap
$815.57B
Enterprise Value€964.90B
Total Cash (Recent Filing)$9.91B
Total Debt (Recent Filing)$42.51B
Price to Earnings (P/E)43.8
Beta0.57
Next Earnings
Apr 30, 2026EPS Estimate
6.05Next Dividend Ex-DateN/A
Dividend Yield0.62%
Share Statistics
EPS (TTM)6.35
Shares Outstanding945,383,700
10 Day Avg. Volume3,393
30 Day Avg. Volume2,150
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)36.37
Price to Sales (P/S)14.81
P/FCF Ratio107.56
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue16.24
Enterprise Value/Gross Profit19.56
Enterprise Value/Ebitda38.14
Forecast
1Y Price Target
$1,057.64Price Target Upside22.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cell Therapy ExpansionAcquisition of Orna broadens the company's cell therapy capabilities by adding a circular RNA platform and in vivo CAR-T approaches that could reduce manufacturing complexity and expand oncology and immunology treatment access.
Financial StrengthA strong balance sheet and reliable cash flow support sustained investment in higher-risk pipeline programs without materially affecting the core diabetes and obesity business.
Product Launch And ManufacturingFavorable launch conditions for an oral incretin, coupled with industry-leading manufacturing capacity and a broad incretin portfolio, position the company to capture meaningful market share in obesity and diabetes care.
Bears Say
Emerging Oral CompetitionAn oral obesity candidate developed in China demonstrated weight-loss results similar to the company's oral data, signaling growing competition that could pressure market share in the oral obesity segment.
Guidance And Share VolatilityMultiple swing factors in the incretin franchise, including unpredictable volume channels and launch execution, create wide guidance ranges and raise the likelihood of share volatility.
In Vivo CAR-T Development RiskIn vivo CAR-T remains an early-stage, high-risk technology with limited large-scale clinical validation and rising competition from major drugmakers, increasing development and commercialization uncertainty.
Eli Lilly & Co News
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was €535.80 and its highest was €971.10 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Eli Lilly & Co’s market cap is $815.57B.
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Apr 30, 2026 which is in 75 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Feb 04, 2026. The company reported €6.354 earnings per share for the quarter, beating the consensus estimate of €5.824 by €0.53.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of €1.291 which represents an annual dividend yield of 0.62%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is 6.05.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 945,383,700 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of €6.354 in its last earnings report, beating expectations of €5.824. Following the earnings report the stock price went up 6.692%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Currently, no hedge funds are holding shares in DE:LLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eli Lilly & Co Stock Smart Score
Company Description
Eli Lilly & Co
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
LLY Company Deck
LLY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a strongly positive operational and financial picture: very large revenue and EPS growth, broad product and pipeline momentum (multiple Phase 3 successes and regulatory submissions), significant manufacturing scale-up, and a constructive 2026 guidance ($80–$83B revenue midpoint +25%). These positives are balanced by meaningful near-term headwinds including price erosion (US price decline ~7% in Q4 and price drag expected in the low-to-mid teens for 2026), higher R&D and commercial spend, some tolerability/discontinuation signals for specific programs, and temporary reimbursement/coverage reductions in Medicaid. On balance the company’s growth drivers, pipeline wins, commercial momentum, and capital allocation outweigh the challenges, but the business will need to manage price pressure and elevated investment levels as it scales.View all DE:LLY earnings summariesLLY Revenue Breakdown
90.47% Net product revenue
9.53% Collaboration and other revenue
LLY Stock 12 Month Forecast
Average Price Target
€1,057.64
▲(22.47% Upside)
Technical Analysis
Options Prices
Currently, No data available
---